This was an easy story to read: well-written and engaging. But there was no meat – just a dessert-like cherry topping of tidbits of a potpourri of a recent abstract from a conference and past research on cherries and purported health benefits.
The cutesy top to the story – “Take two slices of cherry pie and call me in the morning” – conveys a message that is not backed up in the story itself. “It might make a sliver of sense”? Perhaps only if you define a “sliver” as what you can glean from tiny, short-term studies in people – or some stuff in rats.
And the sentence – “Cherry pie contains the same sort of anti-inflammatory compounds as aspirin…” – is misleading. The pie does not contain the compounds, the cherries do. No proof is given that the cherries retain their beneficial compounds if they are, in fact, baked in a pie, because the studies are conducted with cherry juice. This might seem trivial, but it’s misleading.
Accuracy and context matter.
The cost of cherries is not in question (although one of our reviewers recently got a spouse-scolding for NOT checking price and coming home with $18 worth of cherries!)
Many different claims were made in the story from several different studies over time. But only vague descriptions of benefit were provided – no quantification.
The claim that the women “who got the real stuff” had significantly less inflammation, as measured by C-reactive protein (CRP), as compared to those who drank a placebo, is not accurate. The researchers only saw the decrease in CRP in a subset of 12 of the women who had active inflammation and thus elevated CRP.
What’s not mentioned in the story is that in the study on women with OA, only 1 of the 4 serum biomarkers of inflammation (TNF-a) showed a statistically significant decrease.
This is another example of a news story reporting on a surrogate marker (read our primer on this topic), but not on an outcome such as “What difference did that make in their everyday lives?”
Not applicable. We don’t know what the harms of eating cherries might be.
There wasn’t any independent evaluation of the evidence.
And why don’t such stories include links to at least the abstracts of such papers? (The sleep abstract is here. And the fat rats abstract is here.)
The story should have mentioned that Dr. Kuehl appears on the Cherry Marketing Institute’s “power team.”
And there was no independent perspective quoted. Only one author saying his work “could someday provide an alternative treatment” and another author saying “there are some interesting and potentially exciting results on the horizon. Stay tuned.”
In just an additional line or so, the story could have included something about alternatives for inflammatory osteoarthritis. It also could have mentioned other foods that are rich in anti-inflammatory and anti-oxidant compounds.
The availability of cherries is not in question.
The story attempted to paint a broader picture of other cherry research that’s been conducted.
It’s unclear how much the story may have been affected by this news release from The Cherry Marketing institute.
Because more than one researcher was interviewed, we’ll give the story the benefit of the doubt.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Our editorial team was blessed to have Sharon as a contributor during our best years. As this obit states, she was “kind, patient, wise, thoughtful and generous.” Thank you, Sharon; now rest in peace. https://journalism.wisc.edu/news/in-memoriam-sharon-dunwoody-1947-2022/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like